Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Carcinoma, Hepatocellular 52Carcinoma, Renal Cell 25Liver Neoplasms 23Neoplasms 19Carcinoma, Non-Small-Cell Lung 16Breast Neoplasms 16Kidney Neoplasms 11Leukemia, Myeloid, Acute 9Melanoma 8Glioblastoma 8Sarcoma 7Prostatic Neoplasms 7Neoplasm Metastasis 7Brain Neoplasms 7Thyroid Neoplasms 6Ovarian Neoplasms 6Lung Neoplasms 6Pancreatic Neoplasms 5Gliosarcoma 5Urinary Bladder Neoplasms 4Recurrence 4Leukemia, Myelomonocytic, Chronic 4Leukemia 4Carcinoma 4Rectal Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Multiple Myeloma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leiomyosarcoma 3

Interventions

fludarabine phosphate 28Peripheral Blood Stem Cell Transplantation 25Cyclophosphamide 24Whole-Body Irradiation 22Busulfan 22Tacrolimus 19Mycophenolic Acid 19Methotrexate 15Antilymphocyte Serum 13Cyclosporine 12Melphalan 9Filgrastim 9Cytarabine 9Etoposide 8Cord Blood Stem Cell Transplantation 7fludarabine 6Thiotepa 6Methylprednisolone 6Imatinib Mesylate 5Granulocyte Colony-Stimulating Factor 5thymoglobulin 4merphos 4Sirolimus 4Rituximab 4Radiotherapy 4Flow Cytometry 4Dexamethasone 4Dasatinib 4Cyclosporins 4Calcium Dobesilate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Blast Crisis × Sorafenib × Clear all
NCT01445080 2021-02-02

Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

National Cancer Institute (NCI)

Phase 1/2 Completed
70 enrolled 26 charts
LymphoidMyeloidOther hematologic neoplasm

Blast Crisis, Recurrence, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

Data powered by HemOnc (CC BY 4.0) Colophon âš¡